Pascal Soriot defends firm and says its booster jab has performed well against new Covid variants in trials
The chief executive of AstraZeneca has defended the company against “armchair generals” and said its vaccine has a future.
Pascal Soriot disclosed the UK had priority access to the jab in a deal with Oxford University in return for investment and that it was only slightly less effective against the India variant than the strain identified in Kent.
